Seroprevalence of hepatitis virus B seropositive in the patients with cholangiocarcinoma: a summary.
The exact etiology of cholangiocarcinoma remains undetermined. One of the related risk factors for its development might be chronic viral hepatitis infection. Concerning hepatitis B infection, a correlation with cholangiocarcinoma has been documented. Here, we summarize knowledge on the prevalence of hepatitis B seropositivity among patients with cholangiocarcinomas. According to the literature review, five reports were recruited for further metanalysis, covering 565 cases. The overall prevalence of seropositive cancer was 14.5% (83/565). Further analysis revealed no correlation between prevalence rate and nationality of the studied population (P > 0.05). Therefore, hepatitis B infection might be a contributing factor for cholangiocarcinoma development.
Wiwanitkit
Viroj
V
Department of Laboratory Medicine, Faculty of Medicine,Chulalongkorn University, Bangkok 10330 Thailand. wviroj@pioneer.netserv.chula.ac.th
D001650:Bile Duct Neoplasms / Q000453:epidemiology* / Q000821:virology*; D016009:Chi-Square Distribution; D018281:Cholangiocarcinoma / Q000453:epidemiology* / Q000821:virology*; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology* / Q000821:virology; D006510:Hepatitis B Antibodies / Q000097:blood*; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D008297:Male; D015995:Prevalence; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D013785:Thailand / Q000453:epidemiology
D006510:Hepatitis B Antibodies